Physician profile
Rajeev Gupta
NPI 1417936261
$5,648.82
in general payments reported to CMS, 2019-2025
40 companies · $854 in 2025
The $854 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $740 · 2021: $1,089 · 2022: $723 · 2023: $498 · 2024: $573 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Education: $60.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.93 |
| Education | $60.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $455.58 | 2019-2022 | |
| Novo Nordisk INC | $446.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $424.30 | 2019-2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $420.42 | 2020-2025 | Rexulti |
| Mylan Specialty L.P. | $336.49 | 2019-2023 | Yupelri |
| Amgen INC. | $332.07 | 2020-2025 | Otezla, Repatha, Otezla |
| Allergan, INC. | $304.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $297.53 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $289.18 | 2020-2025 | |
| Corcept Therapeutics | $262.36 | 2024 | Korlym |
| Astellas Pharma US INC | $251.65 | 2019-2023 | Veozah, Myrbetriq |
| Lilly USA, LLC | $251.19 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $211.21 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Pfizer INC. | $180.05 | 2019-2025 | |
| Radius Health, INC. | $129.44 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.